Bone-Building Peptide Teriparatide Outperformed Standard Treatment for Steroid-Induced Bone Loss

An 18-month randomized, double-blind, controlled trial enrolling 428 men and women (ages 22-89) with osteoporosis who had been taking glucocorticoids (≥5 mg prednisone equivalent daily) for at least 3 months. Patients were randomized 1:1 to receive either teriparatide (20 μg daily injection) or alendronate (10 mg daily oral). The primary outcome was change in lumbar spine bone mineral density, with secondary outcomes including hip BMD, bone turnover markers, and fracture incidence.

Millions of people take glucocorticoids (like prednisone) for conditions such as rheumatoid arthritis, asthma, and autoimmune diseases, and bone loss is one of the most serious long-term side effects. This landmark NEJM trial showed that the peptide teriparatide doesn't just slow bone loss (like alendronate does) — it actively builds new bone, resulting in more than twice the bone density gain and a 10-fold reduction in spinal fractures. It changed how clinicians think about treating steroid-induced osteoporosis.

This trial was pivotal in establishing that bone-building (anabolic) therapy is superior to bone-preserving (antiresorptive) therapy for steroid-induced osteoporosis. It helped shift clinical practice toward using teriparatide first in high-risk patients rather than as a last resort. The results also demonstrated that peptide-based therapies can address the root cause of bone loss — insufficient new bone formation — rather than just slowing breakdown.

The trial lasted 18 months, so longer-term comparative outcomes are unknown. Nonvertebral fracture rates were not significantly different, possibly due to insufficient power for this endpoint. More teriparatide patients experienced elevated calcium. Teriparatide requires daily injections while alendronate is oral, affecting real-world adherence. The study was industry-sponsored (Eli Lilly, maker of teriparatide).